
Dionysis Nikolopoulos
@dionysisnik
Researcher at Karolinska Institutet
ID: 1664265697978093569
01-06-2023 13:40:46
21 Tweet
75 Followers
366 Following




CONGRESS #ACR23 | Dionysis Nikolopoulos, Karolinska Institutet, discussed impact of neuropsychiatric #SLE on HRQoL in 2968 pts with SLE from 4 ph-III trials (BLISS-52, BLISS-76, BLISS-SC & EMBRACE). Pts with NPSLE had significantly lower SF-36 PCS (35.7 vs 39.6) & MCS scores (37.3 vs 41.4),


An eye-opener! Absolutely worth reading. A wonderful collaboration with Jinoos Yazdany THEE Ashira Blazer MD @CMLanataMD Dionysis Nikolopoulos ‼️ Spread the news! 🔔





🇮🇹The first paper of the Italian Registry of #pregnancy in #rheumaticdiseases is out!🤰 Cannot express enough gratitude & pride to 🙏outstanding investigators collecting data since 2018 🙏SIR - Società Italiana di Reumatologia for the support 🙏>1000 patients for participating rmdopen.bmj.com/content/10/2/e…




Post-PEXIVAS, still controversy about plasma exchange in ANCA-assoc vasculitis. Guidelines recommend against routine use, no clear benefit in subgroup analysis, KenWarringtonMD tells #ARANZRA24 that Mayo Clinic have moved away from it. Many good people still use it, though, so…


Congratulations to all winners of the #EMEUNETtop10abstracts at #EULAR2024! Yvonne Tan Dionysis Nikolopoulos Quirine Dumoulin Jack Arnold Tsuneyasu Yoshida🇯🇵→🇺🇸 @m_scherlinger Celina Geiss Shinji Izuka Liubov Petelytska and Blaž Burja Keep following our #EMEUNET socials for updates on each abstract!


#Interferon and #B-cell Signatures Inform #PrecisionMedicine in #Lupus Nephritis 💡Druggable pathways by #lupusnephritis transcriptome 💡Drugs benefit differentially depending on disease phase More: pubmed.ncbi.nlm.nih.gov/38899167/ KIReports By Dionysis Nikolopoulos @JuliusLindblom 3TR-IMI



In the Sept issue ▶️ #APS #SLE by #transcriptomeanalysis 🦋 ❇️ #IFN I-II signature ▶️ highest in SLE-aPL-negative 🔵 Venous ▶️ neutrophils & B cells 🔴 Arterial ▶️ DNA-damage-response & impaired metabolism 🔗 bit.ly/4goyd7R Dionysis Nikolopoulos George Bertsias Ioannis Parodis


Day 1 of the #3TR Annual Meeting is done! ✅ What a fantastic start with insightful presentations, progress updates and breakout sessions! 🙌 We’d also like to thank our host AstraZeneca for making this meeting possible! See you tomorrow for Day 2! #3TR #Gothenburg

